28 results about "Antibody formation" patented technology

The invention discloses a plasma or serum exosome separation method which comprises the following steps: firstly, coupling an antibody for resisting four transmembrane protein CD81 on the surface of an exosome by using a magnetic bead to form an immunomagnetic bead; pretreating a serum / plasma sample, enriching exosomes, co-incubating with the immunomagnetic beads, washing the magnetic beads after incubation capture is completed, and washing off uncombined impurities; after being captured, the exosome can be directly cracked, the magnetic beads are removed for downstream experiments, or the magnetic beads are eluted to obtain the complete exosome. The exosome affinity antibody is matched with the magnetic beads, the plasma / serum sample exosome is separated, the unique affinity separation technology not only can remove high-abundance protein in the serum / plasma sample, but also can eliminate other vesicles with similar membrane structures with the exosome, so that the purity of the separated exosome is far higher than that of the exosome obtained by other separation methods.

Antibodies and other molecules including an antigen binding region of an antibody that immunospecifically binds to a surface unit or a transmembrane unit of a Human endogenous retrovirus-K (HERV-K) Env protein are provided. The antibodies and other molecules typically include six complementarity determining regions (CDRs). In preferred forms the antibodies and other molecules immunospecifically bind to the amino acid sequence SEQ ID NO:223 and / or 224. Chimeric antigen receptors (CAR) formed using the provided antibodies are also provided, as are cell expressing the CAR. Methods of detecting HERV-K Env, and use thereof of various other methods such as diagnostic methods are also provided. Method of treatment for HERV-K Env protein-related diseases and disorders are also provided.

The present technology includes methods for detecting an anti-drug antibody (ADA) that binds an anti-TNFα antibody (target antibody) in a sample comprising incubating the sample with a composition comprising an affinity antibody and a detection antibody, and isolating and detecting the ADAs that form a complex with the affinity antibody and the detection antibody. The technology also includes methods for determining the ADA concentration in a sample and confirming that a sample comprises ADAs. The technology also includes a kit for performing any of the methods of the present technology.

The invention provides a UBC-CK8 / 18 detection kit based on chemiluminescence, and the kit is characterized in that an antibody is immobilized through a streptavidin-biotin system to form a magnetic bead-biotinylated antibody-antigen-acridinium ester labeled antibody compound; after washing, the substrate solution excites the acridinium ester to generate a photon signal, and a relative luminescence unit (RLUs) is captured by a full-automatic chemiluminescence immunoassay instrument, so that rapid and low-cost clinical detection of bladder cancer is realized, and the detection performance is good.

Provided (Ia) are conjugator-functionalized pyrrolobenzodiazepine (PBD) dimer compounds of Formula (I), wherein structures A and B are PBDs and conjugator is a group capable of forming a covalent linkage with an antibody. Also disclosed are antibody-drug conjugates comprising the conjugator-functionalized PBD dimer compounds.

The present invention relates to a method for forming a multispecific antibody from a first and a second homodimeric antibody, comprising the steps of:-providing at least one solution comprising said homodimeric antibody; -loading said at least one solution onto an adsorption chromatography medium such that said homodimer antibody binds to said medium; contacting the bound antibody with a reducing agent; and-eluting the bound antibodies with an elution buffer, thereby obtaining an eluate pool. The method further comprises a step of contacting the bound or eluted antibody with an oxidizing agent after the step of contacting the bound antibody with the reducing agent, thereby forming a multispecific antibody from the first and second homodimeric antibodies. The invention also relates to a pharmaceutical product comprising a multispecific antibody obtained by such a method.

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

The invention provides an IgG (immunoglobulin G) binding type immune activator protein as well as a preparation method and application thereof, and belongs to the technical field of medicines. It is found for the first time that after three Fab binding peptides CFab and N215 are fused, the N215 can be endowed with the IgG antibody binding capacity, the obtained fusion protein N215-CFab3 and the IgG antibody can form a stable compound, and the compound retains the functions of the N215 and the antibody, can mediate binding of the N215 to target cells, remarkably prolongs the half-life period of the N215, promotes proliferation of T and NK cells, and has the advantages of being capable of achieving the purpose of improving the immunogenicity of the N215 and improving the immunogenicity of the N215. The remarkably enhanced in-vivo anti-tumor effect is exerted. A compound formed by the fusion protein N215-CFab3 and an IgG antibody can be used as an immune activator, and has a wide application prospect in immunotherapy of diseases such as tumors and infection.

The invention belongs to the technical field of immunological detection, and particularly discloses a monoclonal antibody resisting human monocyte chemoattractant protein 1, a kit containing the monoclonal antibody and application of the monoclonal antibody. The monoclonal antibody is a paired antibody, comprises a 6H11 antibody and a 1F12 antibody, and can specifically recognize human monocyte chemotactic protein 1. A human MCP-1 antibody (6H11) is coated with an elisa plate to form a solid-phase carrier, the solid-phase carrier is combined with an MCP-1 antigen in a biological sample to be detected, an antibody (1F12) is detected through specific enzyme labeling, a solid-phase antibody-antigen-enzyme labeled antibody compound is formed, and detection is performed through intervention of a chromogenic substrate solution. The detection kit provided by the invention adopts a one-step method, a standard product / sample and an enzyme-labeled antibody are added together for reaction during detection, the reaction time does not exceed 1h, the whole experimental operation steps are few, the time is short, the sensitivity is high, and the precision and the accuracy are good.

This invention belongs to the field of CT imaging technology and relates to a bismuth-based imaging contrast agent and its preparation method. The bismuth-based imaging contrast agent is formed by chelating bismuth ions with DTPA modified with aminosulfonic acid, followed by surface-linking with an antibody. The preparation method includes: a first reaction of DTPA and aminosulfonic acid in the presence of an activator to obtain aminosulfonic acid-modified DTPA; a second reaction of DTPA with an inorganic bismuth salt in a second solvent, followed by pH adjustment to neutral and drying to obtain aminosulfonic acid-modified DTPA chelated with bismuth ions; and a third reaction of the aminosulfonic acid-modified DTPA chelated with bismuth ions with an antibody, followed by drying. The CT imaging contrast agent exhibits excellent CT imaging capabilities, high safety, and tumor cell killing ability.

The present invention discloses an antibody combination for detecting mycobacterial lipoarabinomannan, its application, and a kit, relating to the field of biological detection. The inventors of this application screened and identified various sample types, identifying capture antibodies suitable for LAM antigen capture and detection antibodies suitable for LAM antigen detection. This resulted in a superior antibody combination for LAM antigen detection, which exhibits high sensitivity and specificity and can be used to detect LAM antigens in purified LAM, standard strains of Mycobacterium tuberculosis, clinical isolates, pleural effusions, plasma, and other bodily fluids. This provides a new antibody combination and method for LAM antigen detection, as well as a new method and kit for the auxiliary diagnosis of active tuberculosis.

The present application relates to a kind of based on electrochemiluminescence immunoassay semeglu-tide content detection method, the kit for detecting semeglu-tide and monoclonal antibody pair, it solves the technical problem that the prior art through LC-MS / MS determination semeglu-tide content exists and is complex, detection flux is low, impurity residue, sample loss amount is big and traditional ELISA detection sensitivity is low, it is by the way that one monoclonal antibody reagent AS-MAB01 is coated on electrochemiluminescence microplate, specifically recognizes and combines semeglu-tide in matrix, then another monoclonal antibody AS-MAB02 labeled with ruthenium is added to form sandwich complex, finally, high sensitivity semeglu-tide quantitative detection purpose is achieved by electrochemiluminescence principle.The present application can be used for the quantitative detection of semeglu-tide in mouse, monkey and human-derived serum samples.

The embodiment of the invention provides a PLGF and sFlt-1 double-marker joint detection kit and application. The kit comprises an sFlt-1 labeled antibody, a PlGF labeled antibody, an antibody coated fluorescent magnetic bead working solution, an antibody calibrator, a sample diluent, a cleaning solution, an enzyme solution and an enzyme substrate solution. According to the application, specific capture antibodies of sFlt-1 and PlGF are respectively coupled to different fluorescence coded magnetic beads, so that the specific capture antibodies, an antigen and a detection antibody form a double-antibody sandwich structure, and the double-antibody sandwich structure is cleaned, uniformly mixed and synchronously imaged, so that synchronous and simultaneous testing of sFlt-1 and PlGF in the same sample is realized, and high-resolution quantitative analysis is carried out. Therefore, the application of the joint detection kit significantly simplifies the detection process, reduces the cost, improves the detection flux and efficiency, effectively improves the sensitivity and accuracy of preeclampsia risk assessment, and has important clinical popularization value.

The invention discloses a kappa light chain detection kit and a preparation method, and relates to the technical field of clinical in-vitro detection reagents, the kit is in a double-reagent form, the double reagents comprise a reagent R1 and a reagent R2, the reagent R2 comprises a capture antibody and a detection antibody which can be specifically combined with different epitopes of a kappa light chain, and the detection antibody comprises a reagent R1 and a reagent R2 which can be specifically combined with different epitopes of the kappa light chain. A capture antibody-antigen-detection antibody sandwich structure is formed to improve the hook effect in detection. The kappa light chain detection reagent provided by the invention solves the problems that the existing kappa light chain detection reagent mostly uses a single antibody and a hook effect is easy to occur due to reduction of a HOOK point, a capture antibody-antigen-detection antibody sandwich structure is formed by two antibodies (capture antibody and detection antibody) aiming at different epitopes of an antigen, and the core is a specific binding mode, so that the recognition precision of the antigen can be improved, and the detection accuracy of the kappa light chain detection reagent is improved. And non-specific binding is reduced, the detection sensitivity and HOOK point are greatly improved, and further popularization and application in the market are facilitated.

The invention aims at providing an acute gouty arthritis diagnosis and treatment preparation based on natural antioxidants and a preparation method and application thereof, and belongs to the technical field of nano biomedical materials.The acute gouty arthritis diagnosis and treatment preparation is self-assembled with spheroidic tea polyphenol and acidified rutin as sources and comprises a polyphenol hydroxyl structure of the natural antioxidants, and the natural antioxidants are added into the polyphenol hydroxyl structure of the natural antioxidants; the nano-probe is formed by coating maleoyl bovine serum albumin (MBSA) and then coupling a NOX2 antibody through an antibody drug coupling technology, and the nano-probe with integrated diagnosis and treatment of acute gouty arthritis is constructed. The nano probe can be used for positioning an acute gouty arthritis part in real time under the guidance of near-infrared region imaging; the probe can directionally remove macrophages and microenvironment high-expression reactive oxygen species (ROS), and the preparation method of the probe is simple and easy to implement.

This invention discloses a long-chain carboxyl microsphere, its preparation method, and a kit. The conventional method for preparing polystyrene (PS) carboxyl microspheres is improved by using long-chain carboxyl functional monomers such as 3-methyl-4-pentenoic acid and 5-methyl-5-hexenoic acid, which have similar structures. Using these functional monomers to prepare microspheres promotes longer carboxyl chains, overcoming steric hindrance. Crosslinking the prepared microspheres with amino-containing small-molecule haptens allows for turbidity reactions with corresponding antibodies, eliminating the need for pre-crosslinking of small-molecule antigens with proteins. A kit constructed using the conjugated small-molecule microspheres exhibits satisfactory calibration curves and can be used to detect the content of corresponding substances in samples.

The invention discloses a novel immunodetection method and application. The immunodetection method comprises the following steps: coating a captured antibody and a single-site recognition antigen on a solid-phase carrier; adding a to-be-detected sample and a biotin-labeled mixed detection antibody for incubation, so that the target antigen forms a double-antibody sandwich compound, and the single-site recognition antigen and the detection antibody form a competitive compound; after streptavidin marked by chemiluminescence is added for incubation, signal values of the two compounds are detected; whether interference exists or not is judged and detected by comparing the double signals, and the content of the target antigen is determined. The immunodetection method can effectively identify cross interference and hook effect, and improves the accuracy and reliability of multi-index detection.

The present technology includes a method for detecting anti-drug antibodies (ADAs) that bind to anti-TNF [alpha] antibodies (target antibodies) in a sample, the method comprising incubating the sample with a composition comprising an affinity antibody and a detection antibody, and isolating and detecting the ADAs that form complexes with the affinity antibody and the detection antibody. The techniques also include methods for determining the concentration of ADA in a sample and confirming that the sample contains ADA. The technology also includes a kit for performing any of the methods of the technology.

The invention relates to the technical field of biological detection, and provides a visual allergy-infection duplex detection device based on a partitioned nanofiber membrane. According to the device, a functional nanofiber membrane is integrally constructed through an electrostatic spinning technology, hydrophilic PVA nanofibers are taken as a substrate, bifunctional integration is realized through precise partition design in combination with immunochromatography and a color development mechanism, an allergy detection region adopts PVA nanofibers to encapsulate an anti-human ECP capture antibody and a colloidal gold-anti-ECP detection antibody, and the sensitivity of the detection region is greatly improved. An antibody-antigen compound is formed to capture ECP in saliva and display a red signal; the infection detection area adopts gelatin and PLGA (poly (lactic-co-glycolic acid)) nanofiber to encapsulate Fe3O4 nano enzyme and 3, 3 ', 5, 5'-tetramethyl benzidine. The detection nanofiber membrane provided by the invention has the capability of joint detection of allergy and infection, good detection efficiency and long-term stability, can realize dynamic monitoring of the allergy state and infection risk of a COPD patient through a non-invasive saliva sample, and provides indication for prognosis management of the COPD patient.

This invention relates to a protein detection method. Specifically, the method introduces magnetic beads to capture antibodies that bind to the target protein structure, forming a triple-antibody sandwich protein-magnetic bead complex. This complex is then detected to obtain the target protein detection result. The method of this invention exhibits good stability, high sensitivity, high efficiency, low background signal, and simple operation steps.

The present invention provides a composition comprising the following thyroid stimulating hormone receptor (TSHR) peptides: (i) all or a portion of the amino acid sequence KKKKYVSIDVTLQQLESHKKK (SEQ ID NO: 1), or a portion thereof, or a sequence having at least 60% sequence identity to SEQ ID NO: 1; and (ii) all or a portion of the amino acid sequence GLKMFPDLTKVYSTD (SEQ ID NO: 2), or a portion thereof, or a sequence having at least 60% sequence identity to SEQ ID NO: 2. The invention also relates to the use of such compositions in the prevention or inhibition of activated autoantibody formation in Graves's disease.

The invention belongs to the technical field of biology, and particularly discloses an anti-aeromonas cainea egg yolk antibody as well as a preparation method and application thereof. The invention relates to an anti-aeromonas cainea egg yolk antibody, which is prepared by immunizing laying hens by using an inactivated vaccine prepared from aeromonas cainea RDBAE-24091, collecting hyper-immune eggs, and separating and purifying the hyper-immune eggs to obtain the anti-aeromonas cainea egg yolk antibody. The method comprises the following steps: carrying out inactivation treatment on aeromonas caviridis RDBAE-24091 to prepare an inactivated vaccine, inoculating the vaccine into a laying hen body, inducing the laying hen to generate a specific immune reaction, enabling an immune system of the laying hen to generate an antibody aiming at the aeromonas caviridis to form a hyper-immune egg, carrying out separation and purification on the hyper-immune egg, removing impurities in egg liquid, and carrying out purification on the hyper-immune egg so as to obtain the laying hen feed. A high-purity and high-activity target product is obtained, and an egg yolk antibody product which aims at the aeromonas cainea and has both green safety and targeted antibacterial efficiency is provided.

The invention discloses an antibody combined with an E2-E2 antibody compound, and relates to the field of antibodies. The antibody combined with the E2-E2 antibody compound comprises a heavy chain complementarity determining region and a light chain complementarity determining region, the antibody is strongly combined with the E2 and the compound formed by the E2 antibody, is not combined with the free E2 antibody or is not combined with the free E2, the antibody provides an important raw material source for the detection of the E2, and the detection cost is reduced. And the antibody has good sensitivity and activity, good detection linear relationship and relatively high clinical correlation.

The invention includes a method of treatment using a therapeutic agent for a condition which the therapeutic agent is effective. The method includes (a) at least one pre-treatment administration to a patient of a therapeutic drug conjugate, wherein the therapeutic drug conjugate is in the form of T-L-C, wherein T comprises the therapeutic agent, L comprises a linker and C comprises a cytotoxic agent; and (b) a first therapeutic administration to a patient of the therapeutic agent. The first therapeutic administration of the therapeutic agent is at a therapeutic level for treating the condition for which the therapeutic agent is effective and the at least one pre-treatment administration of the therapeutic drug conjugate is at a level that is below the therapeutic level for treating the condition with the therapeutic agent alone.

The invention provides a double-enhanced 3D gold nanoflower biosensor as well as a preparation method and application thereof. The biosensor comprises a gold nanoflower electrode AuNS obtained by depositing a gold solution on an SPCE electrode. The sensor can be used for noninvasive detection of hormones. The method specifically comprises the following steps: firstly, modifying an antibody for capturing a target to the surface of a gold nanoflower electrode; then dropwise adding a sample on the electrode, and then adding a biotin modified antibody to form a sandwich structure for antibody recognition; then, an SA-HRP solution is added, and tyramine-biotin and HRP are deposited on the electrode through biotin-streptavidin combination; and finally, adding an SA-HRP solution, and detecting the redox current of the HRP catalyzed TMB / HO system by a chronoamperometry to realize the quantitative detection of the antigen concentration. According to the invention, the free hormone protein in saliva can be efficiently detected with high specificity and high sensitivity.

The present application relates to a series of 2'-deoxy-2',2'-difluoro cytidine (2',2'-difluoro 2'-deoxycytidine, dFdC, gemcitabine) Protide and antibody specific to tumor antigen form conjugates and its preparation method and application in the field of treatment. Further, the present application provides a series of antibody-linker-2'-deoxy-2',2'-difluoro cytidine Protide conjugate to form antibody drug conjugate (ADC). The structural features are mainly in the 5'-phosphate phenylamide amino acid ester corresponding group in the structure of 2'-deoxy-2',2'-difluoro cytidine and the linker for linkage, and then coupled with the corresponding tumor specific antibody to form ADC. These ADCs target antigens on tumor cells, endocytose into tumor cells, release the drug 2'-deoxy-2',2'-difluoro cytidine monophosphate, kill tumor cells, and cause tumor cell apoptosis.

The invention relates to the technical field of biology, in particular to monatomic nano-enzyme as well as a preparation method and application thereof. According to the present invention, the monatomic nano-enzyme is provided, the monatomic nano-enzyme uses the carbon quantum dot as the carrier, the carrier is loaded with the monatomic dispersed iron active center, the Fe active center is derived from the aberration heme, and the surface of the monatomic nano-enzyme is modified with the PD-L1 antibody. Carbon quantum dots (CQDs) are used as a carrier, aberration heme is used as a Fe source, the electron structure and electron cloud density of a central active metal atom Fe are accurately regulated and controlled through changes of an aberration heme coordination environment and an electron structure, high-efficiency catalytic activity monatomic nano-enzyme is prepared, a targeted PD-L1 antibody is modified on C coordination in oxidized CQDs, and the high-efficiency catalytic activity monatomic nano-enzyme is obtained. The targeted monatomic nano-enzyme which can be enriched in the tumor microenvironment of prostatic cancer is formed, so that the tumor immune microenvironment can be improved, and the anti-tumor effect can be effectively improved.

The application discloses a liver cancer diagnosis and treatment integrated reagent composition and a preparation method thereof, and the preparation method comprises the following steps: under light-proof conditions, a TK1 antibody working solution is added into an HgC-Dots working solution, and stirring reaction is carried out at room temperature, so that the HgC-Dots and the TK1 antibody form a stable coupling complex system, and the liver cancer diagnosis and treatment integrated reagent composition is prepared. The application fully utilizes the fluorescence imaging characteristics and the targeted treatment effect on tumors of the HgC-Dots, and combines the liver cancer targeted recognition ability of the TK1 antibody, so that specific targeted fluorescence tracing and diagnosis and treatment cooperation on liver cancer cells are realized.